Amira Pharmaceuticals, Inc.

Panmira Pharmaceuticals, LLC

Deborah Volkots

Nicholas Simon Stock

John Howard Hutchinson

Brian Andrew Stearns

Thomas Jon Seiders

Jeannie M Arruda

Jill Melissa Scott

Jeffrey Roger Roppe

Lucy Xiumin Zhao

Yen Truong

Bowei Wang

Ryan Christopher Clark

Heather Renee Coate

Timothy Andrew Parr

David Nathan Zalatan

Yem Pham Truong

Yen Pham Truong

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Polycyclic compounds as lysophosphatidic acid receptor antagonists

Described herein are compounds that are inhibitors of autotaxin. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such inhibitors, alone and in combination with other compounds, for treating autotaxin-dependent or autotaxin-mediated conditions or diseases.

Autotaxin inhibitors and uses thereof

Compounds as lysophosphatidic acid receptor antagonists

Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis

Described herein are heteroaryl compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the heteroaryl compounds described. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.

[object Object]

Described herein are compounds that are antagonists of PGDreceptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGDreceptors. Also described herein are methods of using such antagonists of PGDreceptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD-dependent or PGD-mediated conditions or diseases.

N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors

Described herein are compounds that are antagonists of PGDreceptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGDreceptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD-dependent or PGD-mediated conditions or diseases.

Growing community of inventors

New York, NY, United States of America

Deborah Volkots